UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Nature reviews. Drug discovery, 2022-07, Vol.21 (7), p.509-528

2022

Volltextzugriff (PDF)

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Cancer cell, 2015-09, Vol.28 (3), p.285-295

2015

Volltextzugriff (PDF)

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

PloS one, 2016-09, Vol.11 (9), p.e0161779

2016

Volltextzugriff (PDF)

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Nature reviews. Cancer, 2015-08, Vol.15 (8), p.457-472

2015

Volltextzugriff (PDF)

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy

Clinical cancer research, 2018-10, Vol.24 (20), p.5058-5071

2018

Volltextzugriff (PDF)

Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

Nature communications, 2019-08, Vol.10 (1), p.3850-13, Article 3850

2019

Volltextzugriff (PDF)

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

PLoS pathogens, 2016-01, Vol.12 (1), p.e1005349-e1005349

2016

Volltextzugriff (PDF)

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of clinical oncology, 2010-07, Vol.28 (19), p.3167-3175

2010

Volltextzugriff (PDF)

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

Proceedings of the National Academy of Sciences - PNAS, 2017-05, Vol.114 (21), p.E4223-E4232

2017

Volltextzugriff (PDF)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Annals of the New York Academy of Sciences, 2013-07, Vol.1291 (1), p.1-13

2013

Volltextzugriff (PDF)

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis

Critical care (London, England), 2013-01, Vol.17 (3), p.R85-R85, Article R85

2013

Volltextzugriff (PDF)

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

Cancer immunology research, 2017-02, Vol.5 (2), p.106-117

2017

Volltextzugriff (PDF)

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies

Clinical cancer research, 2013-01, Vol.19 (2), p.357-366

2013

Volltextzugriff (PDF)

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Cancer cell, 2015-10, Vol.28 (4), p.543-543

2015

Volltextzugriff (PDF)

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

PloS one, 2018-06, Vol.13 (6), p.e0198158

2018

Volltextzugriff (PDF)

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of clinical oncology, 2023-02, Vol.41 (4), p.715-723

2023

Volltextzugriff (PDF)

Checkpoint Blockade in Cancer Immunotherapy

Advances in Immunology, 2006-01, Vol.90, p.297-339

2006

Volltextzugriff (PDF)

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs

International immunology, 2007-10, Vol.19 (10), p.1223-1234

2007

Volltextzugriff (PDF)

Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3

The Journal of immunology (1950), 2011-10, Vol.187 (7), p.3493-3498

2011

Volltextzugriff (PDF)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Oncoimmunology, 2020-01, Vol.9 (1), p.1843247-1843247

2020

Volltextzugriff (PDF)

Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV + Cancers

Cancer immunology research, 2020-01, Vol.8 (1), p.131-145

2020

Volltextzugriff (PDF)

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors

Oncoimmunology, 2018-05, Vol.7 (5), p.e1421891-e1421891

2018

Volltextzugriff (PDF)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models

Oncoimmunology, 2018-01, Vol.7 (1), p.e1377873-e1377873

2018

Volltextzugriff (PDF)

1 – 25 von 180

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(166)

Publikationsform

Artikel
(180)

Sprache

Englisch
(180)

Erscheinungsjahr

n.n

Thema

Science & Technology
(111)
Life Sciences & Biomedicine
(97)
Humans
(88)
Animals
(47)
Female
(38)
Mice
(36)
Oncology
(36)
Biological And Medical Sciences
(34)
Immunology
(34)
Male
(34)
Immunotherapy
(29)
Tumors
(26)
Medical Sciences
(25)
Dermatology
(23)
Adult
(21)
Cancer
(20)
Middle Aged
(20)
Antibodies, Monoclonal - Therapeutic Use
(19)
Melanoma
(19)
Cell Line, Tumor
(18)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(122)
MEDLINE
(103)
Publisher website
(97)
Ovid Journals
(78)
Ingenta
(62)
Access via ScienceDirect (Elsevier)
(41)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(30)
IngentaConnect Journals
(28)
Nature
(15)
Springer journals
(15)
JSTOR
(11)
Nexis Uni
(7)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(6)
Wiley-Blackwell Journals
(6)
BMJ Journals
(6)
Wiley Online Library
(5)
Access via Taylor & Francis
(5)
Taylor & Francis
(5)
Access via Taylor & Francis
(4)
Oxford Journals
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy

Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

Anticancer immunotherapy by CTLA-4 blockade： obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Checkpoint Blockade in Cancer Immunotherapy

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs

Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV + Cancers

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models

Suchergebnisse filtern